Danish biotech company Genmab
Arzerra, also known by its chemical name ofatumumab, is Genmab's only drug on the market and is sold by GlaxoSmithKline
The settlement was also agreed with City of Hope, a California not-for-profit organization, Genmab said.
The dispute concerned two U.S. patents issued to Genentech, and City of Hope, and no further terms of the settlement were disclosed.
The case was initiated by GlaxoSmithKline in October 2009 and has been pending before the United States District Court for the Central District of California.
The two patents expire in December 2018, and the settlement was not expected to affect Genmab's financial guidance for 2012, the company said.
(Reporting by Copenhagen Newsroom; Editing by Dan Lalor)